John Gustafson, MD
Interventional Cardiology · Kalamazoo, MINPI 1992777437
Payments from drug & device makers
Across 200 payments — averaging $42.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$639
- Novartis$565
- Abiomed$435
- Inari Medical, Inc.$402
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$373
- plus $3K from 27 others
What the payments were for
- Travel & lodging$1,72420%
- Food & beverage$6,62178%
- Education$1171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 18 | $3,040 |
| Boston Scientific | 15 | $639 |
| Novartis | 36 | $565 |
| Abiomed | 6 | $435 |
| Inari Medical, Inc. | 4 | $402 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $373 |
| Johnson & Johnson | 21 | $303 |
| Medtronic | 5 | $298 |
| Cordis US CORP. | 3 | $224 |
| Pfizer | 10 | $223 |
| E.r. Squibb & Sons, L.L.C. | 11 | $200 |
| Boehringer Ingelheim | 5 | $196 |
| Stryker | 2 | $163 |
| Amgen | 8 | $151 |
| Shockwave Medical, Inc | 1 | $150 |
| Actelion Pharmaceuticals US, Inc. | 3 | $143 |
| AstraZeneca | 10 | $137 |
| Edwards Lifesciences | 1 | $133 |
| Penumbra, Inc. | 2 | $122 |
| Sanofi-aventis U.S. LLC | 5 | $84 |
| Bridgebio Pharma, Inc. | 3 | $73 |
| Gilead | 3 | $61 |
| Chiesi USA, Inc. | 2 | $53 |
| Bayer | 3 | $51 |
| Teleflex LLC | 3 | $49 |
| Cardinal Health 200 LLC | 1 | $43 |
| Angiodynamics, Inc. | 1 | $35 |
| Imperative Care, Inc | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| BD | 1 | $22 |
| W. L. Gore & Associates, Inc. | 1 | $21 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| Vantis Vascular, Inc. | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,462 in reported general payments places this provider in the 50th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 544 | $615,244 |
| XareltoRivaroxaban | 194 | $210,512 |
| EntrestoSacubitril/Valsartan | 104 | $103,209 |
| Repatha SureclickEvolocumab | 90 | $69,523 |
| Ranolazine ErRanolazine | 228 | $22,614 |
| BrilintaTicagrelor | 19 | $15,389 |
| JardianceEmpagliflozin | 17 | $13,700 |
| Metoprolol Succinate | 565 | $11,316 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 438 | $8,879 |
| Atorvastatin Calcium | 584 | $8,120 |
| Diltiazem 12hr ErDiltiazem Hcl | 12 | $6,855 |
| ClopidogrelClopidogrel Bisulfate | 365 | $5,984 |
| Metoprolol Tartrate | 667 | $5,641 |
| Prasugrel Hcl | 50 | $3,835 |
| Carvedilol | 259 | $3,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $223 | $615,244544 claims |
| Johnson & JohnsonXarelto | $303 | $210,512194 claims |
| NovartisEntresto | $565 | $103,209104 claims |
| AstraZenecaBrilinta | $137 | $15,38919 claims |
| Boehringer IngelheimJardiance | $196 | $13,70017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Kalamazoo
- Vishal GuptaKalamazoo$510K
- Tim FischellKalamazoo$492K
- Frank SaltielKalamazoo$60K
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
- Marcel ZughaibSouthfield$1.2M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.